• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

磷酸化 PRAS40（Thr246）表达在胃癌中的预后作用。

Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer.

机构信息

Department of General Surgery, Zhongshan Hospital, Research Institute of Digestive Diseases, Xiamen University, Xiamen, Fujian Province, China.

Department of Laboratory Diagnosis, Changhai Hospital, Second Military Medical University, Shanghai, China.

出版信息

Arch Med Sci. 2014 Feb 24;10(1):149-53. doi: 10.5114/aoms.2013.36927. Epub 2013 Aug 12.

DOI:10.5114/aoms.2013.36927
PMID:24701227
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3953967/
Abstract

INTRODUCTIONS

Phospho-PRAS40(Thr246) (phosphorylated proline-rich Akt substrate of 40 kilodaltons at Thr246) is a biomarker for phosphatidylinositol 3-kinase (PI3K) pathway activation and AKT inhibitors sensitivity.

MATERIAL AND METHODS

In this study, we immunohistochemically investigated the expression of phospho-PRAS40(Thr246) in 141 gastric cancer tumors, and evaluated its clinicopathological and prognostic significance.

RESULTS

Sixty-four cases (45.4%) were defined as phospho-PRAS40(Thr246) positive. Phospho-PRAS40(Thr246) correlated positively with lymph node metastasis, lymphatic infiltration, vascular infiltration and shorter survival. Furthermore, phospho-PRAS40(Thr246) is an independent prognostic factor for gastric cancer.

CONCLUSIONS

Our data suggest that phospho-PRAS40(Thr246) was frequently expressed in gastric cancers, and correlated with malignant progression and poor prognosis of patients. PI3K pathway-targeted therapies should be considered in the future treatment of gastric cancers.

摘要

简介

磷酸化 PRAS40（Thr246）（丝氨酸/苏氨酸激酶 246 位磷酸化脯氨酸丰富的 Akt 底物 40 千道尔顿）是磷脂酰肌醇 3-激酶（PI3K）通路激活和 AKT 抑制剂敏感性的生物标志物。

材料与方法

在这项研究中，我们通过免疫组织化学方法检测了 141 例胃癌肿瘤中磷酸化 PRAS40（Thr246）的表达，并评估了其临床病理和预后意义。

结果

64 例（45.4%）被定义为磷酸化 PRAS40（Thr246）阳性。磷酸化 PRAS40（Thr246）与淋巴结转移、淋巴浸润、血管浸润和较短的生存时间呈正相关。此外，磷酸化 PRAS40（Thr246）是胃癌的独立预后因素。

结论

我们的数据表明，磷酸化 PRAS40（Thr246）在胃癌中频繁表达，与肿瘤的恶性进展和患者的不良预后相关。未来应考虑针对 PI3K 通路的靶向治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c22/3953967/97e294a108a4/AMS-10-21256-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c22/3953967/8b1eaf3efcd7/AMS-10-21256-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c22/3953967/b1ed5e66d0da/AMS-10-21256-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c22/3953967/97e294a108a4/AMS-10-21256-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c22/3953967/8b1eaf3efcd7/AMS-10-21256-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c22/3953967/b1ed5e66d0da/AMS-10-21256-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c22/3953967/97e294a108a4/AMS-10-21256-g003.jpg

相似文献

1
Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer.磷酸化 PRAS40（Thr246）表达在胃癌中的预后作用。
Arch Med Sci. 2014 Feb 24;10(1):149-53. doi: 10.5114/aoms.2013.36927. Epub 2013 Aug 12.
2
Phospho-PRAS40 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.磷酸化PRAS40可预测HER2阳性转移性乳腺癌患者对曲妥珠单抗的反应。
Oncol Lett. 2015 Feb;9(2):785-789. doi: 10.3892/ol.2014.2744. Epub 2014 Nov 28.
3
Phosphorylation of PRAS40-Thr246 involved in renal lipid accumulation of diabetes.磷酸化 PRAS40-Thr246 参与糖尿病肾脏脂质积累。
J Cell Physiol. 2014 Aug;229(8):1069-77. doi: 10.1002/jcp.24533.
4
Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1.蛋白激酶 B/AKT 对 PRAS40 丝氨酸 246 的磷酸化作用促进了 mTORC1 对丝氨酸 183 的有效磷酸化。
Cell Signal. 2010 Jun;22(6):961-7. doi: 10.1016/j.cellsig.2010.02.002. Epub 2010 Feb 6.
5
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.基于通路的靶向治疗生物标志物鉴定：PI3K 通路抑制剂的个体化肿瘤学。
Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.
6
Insulin-like growth factor-1 induces the phosphorylation of PRAS40 via the PI3K/Akt signaling pathway in PC12 cells.胰岛素样生长因子-1 通过 PI3K/Akt 信号通路诱导 PC12 细胞中 PRAS40 的磷酸化。
Neurosci Lett. 2012 May 10;516(1):105-9. doi: 10.1016/j.neulet.2012.03.068. Epub 2012 Apr 2.
7
Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats.在高脂饮食喂养大鼠的胰岛素靶组织中，胰岛素介导的富含脯氨酸的Akt底物PRAS40的磷酸化受损。
Diabetes. 2006 Dec;55(12):3221-8. doi: 10.2337/db05-1390.
8
Effect of PI3K/Akt Signaling Pathway on PRAS40Thr246 Phosphorylation in Gastric Cancer Cells.PI3K/Akt信号通路对胃癌细胞中PRAS40Thr246磷酸化的影响
Iran J Public Health. 2019 Dec;48(12):2196-2204.
9
PRAS40 signaling in tumor.肿瘤中的PRAS40信号传导
Oncotarget. 2017 Apr 20;8(40):69076-69085. doi: 10.18632/oncotarget.17299. eCollection 2017 Sep 15.
10
Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.富含脯氨酸的Akt底物PRAS40在细胞存活途径和致癌作用中的表达
Acta Pharmacol Sin. 2005 Oct;26(10):1253-8. doi: 10.1111/j.1745-7254.2005.00184.x.

引用本文的文献

1
Anti-Cancer Effects of an Optimised Combination of Ginsenoside Rg3 Epimers on Triple Negative Breast Cancer Models.人参皂苷Rg3差向异构体优化组合对三阴性乳腺癌模型的抗癌作用
Pharmaceuticals (Basel). 2021 Jun 30;14(7):633. doi: 10.3390/ph14070633.
2
The Roles of Post-Translational Modifications on mTOR Signaling.翻译：翻译后修饰在 mTOR 信号通路中的作用。
Int J Mol Sci. 2021 Feb 11;22(4):1784. doi: 10.3390/ijms22041784.
3
High PRAS40 mRNA expression and its role in prognosis of clear cell renal cell carcinoma.高PRAS40 mRNA表达及其在透明细胞肾细胞癌预后中的作用。

本文引用的文献

1
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.基于通路的靶向治疗生物标志物鉴定：PI3K 通路抑制剂的个体化肿瘤学。
Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.
2
Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1.蛋白激酶 B/AKT 对 PRAS40 丝氨酸 246 的磷酸化作用促进了 mTORC1 对丝氨酸 183 的有效磷酸化。
Cell Signal. 2010 Jun;22(6):961-7. doi: 10.1016/j.cellsig.2010.02.002. Epub 2010 Feb 6.
3
The PI3K pathway as drug target in human cancer.
Transl Androl Urol. 2020 Aug;9(4):1650-1660. doi: 10.21037/tau-20-741.
4
PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.PRAS40 磷酸化与头颈部癌细胞中胰岛素样生长因子-1 受体诱导的表皮生长因子受体抑制耐药相关。
Mol Cancer Res. 2020 Sep;18(9):1392-1401. doi: 10.1158/1541-7786.MCR-19-0592. Epub 2020 May 28.
5
Cucurbitacin B and cisplatin induce the cell death pathways in MB49 mouse bladder cancer model.葫芦素 B 和顺铂诱导 MB49 小鼠膀胱癌模型中的细胞死亡途径。
Exp Biol Med (Maywood). 2020 May;245(9):805-814. doi: 10.1177/1535370220917367. Epub 2020 Apr 6.
6
Effect of PI3K/Akt Signaling Pathway on PRAS40Thr246 Phosphorylation in Gastric Cancer Cells.PI3K/Akt信号通路对胃癌细胞中PRAS40Thr246磷酸化的影响
Iran J Public Health. 2019 Dec;48(12):2196-2204.
7
PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40).PIM1激酶通过抑制富含脯氨酸的40 kDa Akt底物（PRAS40）促进胆囊癌细胞增殖。
J Cell Commun Signal. 2019 Jun;13(2):163-177. doi: 10.1007/s12079-018-00503-5. Epub 2019 Jan 21.
8
PRAS40 signaling in tumor.肿瘤中的PRAS40信号传导
Oncotarget. 2017 Apr 20;8(40):69076-69085. doi: 10.18632/oncotarget.17299. eCollection 2017 Sep 15.
9
In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines.口服铂（IV）前药奥沙铂和热休克蛋白90（HSP90）抑制剂ganetespib对一组胃癌细胞系的体外细胞毒性活性
J Cancer. 2017 Jul 1;8(10):1733-1743. doi: 10.7150/jca.17816. eCollection 2017.
10
A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma.一种临床可行的多重蛋白质组免疫测定法作为胰腺导管腺癌的新型功能诊断方法。
Oncotarget. 2017 Apr 11;8(15):24250-24261. doi: 10.18632/oncotarget.15653.
PI3K 通路作为人类癌症的药物靶点。
J Clin Oncol. 2010 Feb 20;28(6):1075-83. doi: 10.1200/JCO.2009.25.3641. Epub 2010 Jan 19.
4
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.肿瘤标志物驱动的早期临床试验：药物开发的范式转变。
Cancer J. 2009 Sep-Oct;15(5):406-20. doi: 10.1097/PPO.0b013e3181bd0445.
5
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.PI3K/mTOR 通路的激活发生在大多数成人低级别胶质瘤中，并预测患者的生存。
J Neurooncol. 2010 Mar;97(1):33-40. doi: 10.1007/s11060-009-0004-4. Epub 2009 Aug 25.
6
Gastric cancer in the era of molecularly targeted agents: current drug development strategies.分子靶向药物时代的胃癌：当前的药物研发策略
J Cancer Res Clin Oncol. 2009 Jul;135(7):855-66. doi: 10.1007/s00432-009-0583-7. Epub 2009 Apr 11.
7
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.雷帕霉素在复发性PTEN基因缺失胶质母细胞瘤患者I期试验中的抗肿瘤活性。
PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.
8
mTOR, translation initiation and cancer.哺乳动物雷帕霉素靶蛋白、翻译起始与癌症
Oncogene. 2006 Oct 16;25(48):6416-22. doi: 10.1038/sj.onc.1209888.
9
mTOR and cancer: insights into a complex relationship.雷帕霉素靶蛋白（mTOR）与癌症：对复杂关系的深入洞察
Nat Rev Cancer. 2006 Sep;6(9):729-34. doi: 10.1038/nrc1974. Epub 2006 Aug 17.
10
Epidemiology of gastric cancer.胃癌流行病学
World J Gastroenterol. 2006 Jan 21;12(3):354-62. doi: 10.3748/wjg.v12.i3.354.